KALAMAZOO, MI -- Scientists at Western Michigan University Homer Stryker School of Medicine (WMed) have made a ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

A research team at Western Michigan University Homer Stryker M.D. School of Medicine has made a significant discovery.

The case was a tricky one, a surgery was inevitable. The patient had lost a lot of blood. He was also in severe pain. Then, ...

A team of researchers at Western Michigan University's Homer Stryker M.D. School of Medicine has made a monumental ...

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program.

Using a handheld dynamometer to assess hip flexion and abduction strength during dialysis was reliable and safe, researchers found in a cross-sectional study.“Subjects in stages 3 and 4 of [chronic ...

Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price ...

Jason Yondura’s cellphone rings, and the caller has a number he doesn’t recognize. Though it’s most likely a spam call, ...

A 55-year-old man suffering from Autosomal Dominant Polycystic Kidney Disease (ADPKD) has successfully undergone a complex ...

In an indication that has proved difficult for biopharma to conquer, Regulus Therapeutics Inc. disclosed further positive data from its ongoing phase Ib study testing RGLS-8429 in autosomal dominant ...

Regulus Therapeutics Inc.’s RGLS share price has dipped by 17.09%, which has investors questioning if this is right time to ...